Sonnet BioTherapeutics (SONN) Insider Trading & Ownership $1.54 0.00 (0.00%) As of 01/21/2025 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Sonnet BioTherapeutics (NASDAQ:SONN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.00%Number OfInsiders Buying(Last 3 Years)4Amount OfInsider Buying(Last 3 Years)$105,416.74Number OfInsiders Selling(Last 3 Years)0 Get SONN Insider Trade Alerts Want to know when executives and insiders are buying or selling Sonnet BioTherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SONN Insider Buying and Selling by Quarter Sonnet BioTherapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/14/2023Susan DexterInsiderBuy454$15.40$6,991.60 5/30/2023Albert D DyrnessDirectorBuy1,057$10.34$10,929.38 5/17/2023Nailesh BhattDirectorBuy1,136$5.06$5,748.16 5/15/2023Pankaj MohanCEOBuy16,890$4.84$81,747.60 (Data available from 1/1/2013 forward) SONN Insider Trading Activity - Frequently Asked Questions Who is on Sonnet BioTherapeutics's Insider Roster? The list of insiders at Sonnet BioTherapeutics includes Albert D Dyrness, Nailesh Bhatt, Pankaj Mohan, and Susan Dexter. Learn more on insiders at SONN. What percentage of Sonnet BioTherapeutics stock is owned by insiders? 2.00% of Sonnet BioTherapeutics stock is owned by insiders. Learn more on SONN's insider holdings. Which Sonnet BioTherapeutics insiders have been buying company stock? The following insiders have purchased SONN shares in the last 24 months: Albert D Dyrness ($10,929.38), Nailesh Bhatt ($5,748.16), Pankaj Mohan ($81,747.60), and Susan Dexter ($6,991.60). How much insider buying is happening at Sonnet BioTherapeutics? Insiders have purchased a total of 19,537 SONN shares in the last 24 months for a total of $105,416.74 bought. Sonnet BioTherapeutics Key ExecutivesDr. Pankaj Mohan Ph.D. (Age 59)Founder, Chairman, CEO & President Compensation: $927kDr. John K. Cini Ph.D. (Age 71)Chief Scientific Officer & Co-Founder Compensation: $602.48kMr. Jay Cross (Age 53)Chief Financial Officer Compensation: $603.42kMr. Donald J. Griffith CPA (Age 75)CPA, Controller & Director Compensation: $134.05kMs. Susan Dexter (Age 69)Chief Technical Officer Dr. Richard T. Kenney FACP (Age 66)M.D., Chief Medical Officer Mr. Manuel DafonsecaHead of Clinical Operations More Insider Trading Tools from MarketBeat Related Companies BFRG Insider Ownership BTAI Insider Ownership PIRS Insider Ownership MEIP Insider Ownership FNCH Insider Ownership BCTX Insider Ownership NKGN Insider Ownership COEP Insider Ownership GLYC Insider Ownership SYBX Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (NASDAQ:SONN) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
